ArticleAsian Pacific journal of cancer prevention : APJCP2025
Assessment of Cytotoxicity, Impact on Cell Migration and Apoptotic Modulation of Acteoside and Plantamajoside on Human Breast Adenocarcinoma (MCF-7).
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antioxidants Acteoside and Orientin as Emerging Agents in Synergistic Cancer Therapy: A Focus on Innovative Applications.Antioxidants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the anticancer potential of Acteoside and Plantamajoside using MCF-7 cancer cell line.
methodsIn this study, the half-maximal inhibitory concentration (IC50) values of Acteoside and Plantamajoside were investigated using the Sulforhodamine B (SRB) assay. The IC50 values of both compounds were utilized in the clonogenic and scratch wound assays to assess cell survival and migration, respectively. The cells with treatments were also analyzed using the Caspase 3/7 assay to determine their capability to induce cell apoptosis. Network Pharmacology was used to evaluate their probable protein targets and pharmacological mechanisms.
resultsActeoside and Plantamajoside exhibited cytotoxic activity against the MCF-7 cancer cell line in vitro, with IC50 values of 134.83 μg/mL and 225.10 μg/mL, respectively. This was further supported by clonogenic assay, which showed a difference in colony formation following treatment with ACT and PMS, compared to the negative control. Specifically, ACT resulted in the formation of only 39.7% of colonies, whereas PMS formed 51.12% of colonies, indicating that these compounds impaired the cells' ability to proliferate and form colonies. Moreover, these compounds were also able to inhibit cell migration as a reduction in the migration area of the MCF-7 cell line was observed. An increase in the percentage of apoptotic cells was also noted post-treatment, which correlated with elevated Caspase 3/7 activity, indicating that these compounds may effectively induce cellular apoptosis. In silico predictions demonstrated that the compounds' anticancer effect may be attributed to their interactions with TLR, PI3K, and STAT-all are implicated in the PD-1 checkpoint pathway and PD-L1 expression in cancer.
conclusionBoth Acteoside and Plantamajoside have demonstrated promising anticancer properties by inhibiting the growth and metastasis of MCF-7 cancer cell line. These compounds induce apoptosis, modulate the PD-1 checkpoint pathway, and influence PD-L1 expression, which may indicate possible molecular mechanisms for their anticancer effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.